Cargando…

Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis

Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Nirui, Wang, Qingting, Qiu, Yuanjie, Wang, Yan, Li, Danyang, Li, Manxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239593/
https://www.ncbi.nlm.nih.gov/pubmed/35777041
http://dx.doi.org/10.1097/MD.0000000000029806
_version_ 1784737332614660096
author Shen, Nirui
Wang, Qingting
Qiu, Yuanjie
Wang, Yan
Li, Danyang
Li, Manxiang
author_facet Shen, Nirui
Wang, Qingting
Qiu, Yuanjie
Wang, Yan
Li, Danyang
Li, Manxiang
author_sort Shen, Nirui
collection PubMed
description Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer. METHODS: We searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs). RESULTS: In total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48–2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965–2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856–3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294–2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079–2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793–3.344, P < 0.001). CONCLUSIONS: Elevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers.
format Online
Article
Text
id pubmed-9239593
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92395932022-06-30 Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis Shen, Nirui Wang, Qingting Qiu, Yuanjie Wang, Yan Li, Danyang Li, Manxiang Medicine (Baltimore) Research Article Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer. METHODS: We searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs). RESULTS: In total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48–2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965–2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856–3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294–2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079–2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793–3.344, P < 0.001). CONCLUSIONS: Elevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers. Lippincott Williams & Wilkins 2022-06-30 /pmc/articles/PMC9239593/ /pubmed/35777041 http://dx.doi.org/10.1097/MD.0000000000029806 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Shen, Nirui
Wang, Qingting
Qiu, Yuanjie
Wang, Yan
Li, Danyang
Li, Manxiang
Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title_full Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title_fullStr Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title_full_unstemmed Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title_short Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
title_sort clinicopathological and prognostic role of roc1 in neoplasms: a prisma-compliant systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239593/
https://www.ncbi.nlm.nih.gov/pubmed/35777041
http://dx.doi.org/10.1097/MD.0000000000029806
work_keys_str_mv AT shennirui clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis
AT wangqingting clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis
AT qiuyuanjie clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis
AT wangyan clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis
AT lidanyang clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis
AT limanxiang clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis